泽生科技

Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas
ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
Zensun Successfully Raised Approximately ¥504 million (US$76 million)

Twenty year’s innovative research and development in science and drug discovery. A pioneer and leader in revolutionary cardiomyocyte therapies worldwide.

CARDIOMYOCYTE THERAPY | MECHANISM

Core
Technology

Cardiomyocyte Therapy

CORE TECHNOLOGY

World-leading science and cutting-edge technology, focus on the fundamental principle of diseases, target and mechanism-of-action based drug research and development

Leading technology
pathogenesis
mechanism of target

Pipeline

Neucardin®(HFrEF)

Recombinant human neuregulin-1 (Neucardin®), developed by Zensun, is a novel genetically engineered biologic ...
MORE
Neucardin®(HFpEF)

AMI, due to the sharp reduction or interruption of coronary blood supply, can lead to irreversible myocardial cell damage or death.
MORE
Neucardin®(AMI)

AMI, due to the sharp reduction or interruption of coronary blood supply, can lead to irreversible myocardial cell damage or death.
MORE

ABOUT ZENSUN

SCIENCE

PIPELINE

INVESTOR RELATIONS

CAREERS

CONTACT US

Zensun
Address：68 Ju Li Road, Zhangjiang Hi-Tech Park Shanghai, P.R.China
Tel: 86-021-50802627
Zensun USA
Address：12636 High Bluff Dr, Suite 130, San Diego, CA 92130
Tel：858-450-9835

Zensun is Collaborating with The Leibniz-Institut für Alternsforschung-Fritz-Lipmann-Institute.V. to Conduct a Preclinical Study of Neucardin® (recombinant human Neuregulin-1) for The Treatment of Schwannomas

ZENSUN ANNOUNCES THE INVESTIGATION OF NEUCARDIN FOR CHRONIC HEART FAILURE RECEIVES FAST TRACK DESIGNATION FROM THE US FDA

Zensun Successfully Raised Approximately ¥504 million (US$76 million)

CoreTechnology